Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses

Background and objective Individuals with prolactinoma exhibit elevated rates of obesity, metabolic syndrome (MS), and dyslipidemia compared to their healthy counterparts. However, there is a lack of data regarding metabolic variance between male and female prolactinoma patients. Consequently, this study aimed to investigate and compare sex-specific discrepancies in metabolic abnormalities among individuals diagnosed with prolactinoma. Methods In this prospective study, 80 treatment-naïve patients with prolactinoma (12 males and 68 females) underwent clinical assessments and laboratory investigations. The measured parameters included blood glucose, total cholesterol (TC), triglycerides (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), urea, creatinine, uric acid, and blood glucose levels. The patients were treated with cabergoline, a dopamine agonist, and reevaluated after 12 weeks. Results Forty-eight patients had microprolactinomas (all females), and 32 had macroprolactinomas (20 females, 12 males). The mean age was 28.30±7.49 years for females and 28.91±7.12 years for males (p=0.71). The median symptom duration was 12 months (range 1-72 months, IQR 4-16 months), with no significant difference between males (median 12 months, IQR 5-54 months) and females (median 12 months, IQR 10-24 months, p=0.620). The median serum prolactin (PRL) was 988 ng/mL (IQR 471-1,439) in males and 165 ng/mL (IQR 90-425) in females (p<0.05). Males showed higher HbA1c, BGF, TC, TG, LDL-C, and higher rates of obesity, MS, and diabetes mellitus. Treatment with cabergoline resulted in significant improvements in the HbA1c, BGF, TC, TG, and LDL-C levels. Conclusion Males with prolactinomas had larger tumor sizes and higher serum PRL levels than females. Additionally, males exhibited worse metabolic parameters than females. However, there was no significant difference in the duration of symptoms or age at diagnosis between the two groups.

[1]  A. Siddiqi,et al.  Prolactinoma: Clinical Characteristics, Management and Outcome , 2022, Cureus.

[2]  S. Melmed.  Pituitary-Tumor Endocrinopathies. , 2020, The New England journal of medicine.

[3]  J. Abucham,et al.  A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas , 2019, Pituitary.

[4]  M. Fleseriu,et al.  Magnetic resonance imaging in the management of prolactinomas; a review of the evidence , 2020 .

[5]  J. Vymazal,et al.  Role of gamma knife radiosurgery in the treatment of prolactinomas , 2019, Pituitary.

[6]  P. Chanson,et al.  Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability , 2018, Front. Endocrinol..

[7]  K. Toulis,et al.  Males with prolactinoma are at increased risk of incident cardiovascular disease , 2018, Clinical endocrinology.

[8]  C. Torp-Pedersen,et al.  Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality , 2017, Hormone and Metabolic Research.

[9]  M. Bergsneider,et al.  Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention , 2017, Journal of Neurological Surgery Part B: Skull Base.

[10]  N. Pala,et al.  Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline , 2016, Indian journal of endocrinology and metabolism.

[11]  M. Vrkljan,et al.  Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? , 2016, Endocrine research.

[12]  L. Tshibanda,et al.  Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference , 2015, Neuroradiology.

[13]  M. Cosottini,et al.  Lower Prolactin Levels During Cabergoline Treatment are Associated to Tumor Shrinkage in Prolactin Secreting Pituitary Adenoma , 2014, Hormone and Metabolic Research.

[14]  N. Islam,et al.  Demographic characteristics, presentations and treatment outcome of patients with prolactinoma. , 2014, Journal of Ayub Medical College, Abbottabad : JAMC.

[15]  A. Latronico,et al.  Approach to the patient with hypogonadotropic hypogonadism. , 2013, The Journal of clinical endocrinology and metabolism.

[16]  A. Atmaca,et al.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia , 2013, Endocrine.

[17]  C. Villabona,et al.  Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome , 2012, Clinical endocrinology.

[18]  S. Polyzos,et al.  Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience , 2012, Pituitary.

[19]  Sung-Hoon Kim,et al.  Serum prolactin concentrations determine whether they improve or impair β‐cell function and insulin sensitivity in diabetic rats , 2011, Diabetes/metabolism research and reviews.

[20]  K. Hall,et al.  Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy , 2011, Pituitary.

[21]  M. Gadelha,et al.  BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists , 2011, Obesity.

[22]  María Argente-Pla,et al.  Gender-related differences in prolactinomas , 2011 .

[23]  P. Kann,et al.  Prolactinoma and hyperprolactinaemia: a transcultural comparative study between Germany as a western, liberal, industrialised country and Syria as an oriental society with a strong Islamic tradition , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[24]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[25]  J. Romijn,et al.  Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. , 2009, European journal of internal medicine.

[26]  A. Tuzcu,et al.  Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique , 2009, Pituitary.

[27]  T. Hori,et al.  Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. , 2008, The Journal of clinical endocrinology and metabolism.

[28]  M. Gadelha,et al.  Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients , 2008, Journal of endocrinological investigation.

[29]  A. Hirschberg,et al.  Hyperprolactinaemia in 271 women: up to three decades of clinical follow‐up , 2005, Clinical endocrinology.

[30]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[31]  C. Ling,et al.  Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. , 2005, Biochemical and biophysical research communications.

[32]  B. Schaller.  Gender-related differences in prolactinomas. A clinicopathological study. , 2005, Neuro endocrinology letters.

[33]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[34]  P. Cappabianca,et al.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.

[35]  F. Casanueva,et al.  Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. , 2002, European journal of endocrinology.

[36]  H. Nishioka,et al.  Gender-related differences in prolactin secretion in pituitary prolactinomas , 2002, Neuroradiology.

[37]  D. Pauler,et al.  Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[39]  L. Creemers,et al.  Prolactinoma and body weight: a retrospective study. , 1991, Acta endocrinologica.

[40]  A. Luger,et al.  Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo , 1985, Diabetologia.

[41]  Y. Ramot,et al.  A study of the clinical differences between women and men with hyperprolactinemia. , 1996, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.